Limited studies suggest that risk of vascular complications is increased in individuals with MODY compared to individuals without diabetes except for those with glucokinase gene mutation who display no or minimal increase in risk.5 A Finnish cohort of HNF1A-MODY had similar levels of microvascular complications to T1DM and T2DM when matched for diabetes duration and glucose control assessed as glycated haemoglobin (HbA1c). This evidence concerns the gene HNF1A and type 2 diabetes mellitus.